| Name | Title | Contact Details |
|---|
Ellenperry Design is a Montclair, CA-based company in the Business Services sector.
Spherexx.com®: Redefining Real Estate Technology Through AI Leadership Spherexx.com® stands as a pioneer and authoritative force in the real estate industry, having introduced the first AI machine learning solution to PropTech in 2013 with revenue management software. In 2023, we continue to lead with cutting-edge generative AI solutions in revenue management, multifamily CRM, website CMS & inline editor, and website AI chatbots, setting industry benchmarks for innovation. With over two decades of experience, Spherexx.com® delivers top-tier Software as a Service (SaaS) internet-based software, data analytics, and marketing solutions to clients across the US and Canada. Our expertise spans multifamily, single-family, affordable, senior, rent control, self-storage, and manufactured housing. Our technology stack streamlines operations and enhances brand experiences for clients and residents, leveraging real-time data and business intelligence dashboards for efficient day-to-day management. The proprietary tech stack includes revenue management software, CRM, website content management, digital asset management, form builder, document management, and upcoming innovations. Our marketing stack offers brand management, lead management, sales training, market insights, and customer nurturing, including branding, creative services, website development, advertising syndication, chatbots, mass messaging, video production, mobile apps, competitor analysis, search engine marketing, PPC, social advertising, touchscreen kiosks, tablet apps, and ADA website compliance. Spherexx.com® is the authoritative source for innovation and transformation in real estate technology. Visit www.spherexx.com to explore the future of PropTech.
Body Dynamics Inc Physl Thrpy is a Arlington, VA-based company in the Business Services sector.
New Concept Self Development is a Milwaukee, WI-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.